Description

Description

Xiga-Met 5/850mg Tablet is a fixed-dose combination medicine used for the management of type 2 diabetes mellitus in adults, bringing together two anti-diabetic agents that work through entirely different mechanisms. It combines Dapagliflozin, an SGLT2 inhibitor that helps the kidneys remove excess glucose through urine, with Metformin, a biguanide that reduces glucose production in the liver and improves the body’s response to insulin. This dual mechanism allows the tablet to address blood sugar control from two separate angles, making it a useful option for patients who have not achieved sufficient results with Metformin alone or who need the added benefit of glucose excretion through the kidneys. The pack contains 14 tablets, generally intended for a two-week course based on a twice-daily dosing pattern, and this medicine should always be used under the guidance of a qualified physician who can determine the correct fit for the patient’s kidney function and overall health.

Ingredients

Each Xiga-Met 5/850mg Tablet contains Dapagliflozin 5mg together with Metformin Hydrochloride 850mg as its active ingredients. Dapagliflozin works by blocking the SGLT2 protein in the kidneys, reducing glucose reabsorption and encouraging its excretion through urine, while Metformin lowers hepatic glucose output, slows intestinal sugar absorption, and enhances insulin sensitivity in peripheral tissues. The tablet also contains inactive excipients such as microcrystalline cellulose, povidone, croscarmellose sodium, magnesium stearate, and a film-coating layer that protects the tablet and supports smooth swallowing.

Dosage Form

Xiga-Met 5/850mg is manufactured as a film-coated oral tablet formulated to deliver both active ingredients together in a single dose. The tablets are packed in blister strips that shield them from moisture and light exposure, helping preserve their effectiveness until the printed expiry date.

Uses

Xiga-Met 5/850mg Tablet is used to improve blood sugar control in adults with type 2 diabetes mellitus who benefit from a combined treatment approach. The Dapagliflozin component works independently of insulin by promoting glucose loss through urine, while the Metformin component reduces the amount of sugar the liver releases into the bloodstream and helps the body’s cells use insulin more effectively. Together, these two mechanisms often provide more comprehensive blood sugar control than either medicine alone, particularly for patients who need additional support beyond Metformin monotherapy. This tablet is generally prescribed as part of a broader diabetes management plan that includes dietary adjustments, regular physical activity, and periodic monitoring of blood sugar and kidney function, aiming to reduce the long-term risks associated with poorly controlled diabetes.

How to Use

Xiga-Met 5/850mg Tablet should be taken exactly as prescribed by the doctor, generally with meals to help reduce the digestive discomfort that can be linked to the Metformin component. The tablet should be swallowed whole with a glass of water and should not be crushed or chewed unless specifically advised otherwise. Patients should also maintain good hydration while on this medicine, as the Dapagliflozin component increases urine output. Taking the tablet consistently at the same times each day supports steady blood sugar control. If a dose is missed, it should be taken as soon as remembered, unless the next dose is nearly due, in which case the missed dose should be skipped rather than doubled.

Side Effects

Because Xiga-Met combines two different mechanisms of action, its side effects reflect both components. Commonly reported effects linked to Metformin include nausea, diarrhea, stomach discomfort, and a metallic taste, which often ease as the body adjusts. Effects associated with Dapagliflozin may include increased urination, genital yeast infections, and urinary tract infections due to higher glucose levels being excreted through urine. Some patients may also notice mild dizziness or symptoms of dehydration if fluid intake is insufficient. In rare but serious cases, symptoms of lactic acidosis (unusual muscle pain, difficulty breathing, extreme tiredness) linked to Metformin, or euglycemic diabetic ketoacidosis (nausea, vomiting, abdominal pain) linked to Dapagliflozin, may occur and require urgent medical attention. Any severe, persistent, or unusual symptoms should be reported to a doctor promptly.

Pregnancy & Breastfeeding

Xiga-Met 5/850mg Tablet is generally not recommended during pregnancy, as both the SGLT2 inhibitor and biguanide components are typically replaced with alternative treatments once pregnancy is confirmed, since blood sugar management during pregnancy usually follows a different protocol. Women who are pregnant, planning a pregnancy, or currently breastfeeding should inform their doctor before starting or continuing this medicine so that safer options can be explored. Breastfeeding mothers should also seek medical advice, as the safety of this combination during lactation has not been clearly established.

Storage Instructions

Store Xiga-Met 5/850mg Tablets in a cool, dry place away from direct sunlight and excess humidity, ideally at a temperature below 30°C. Keep the tablets in their original blister packaging until ready for use, and store them securely out of the reach and sight of children and pets. Avoid storing this medicine in bathrooms or other humid areas, and do not freeze the tablets. Always check the expiry date before use, and dispose of any expired or unused tablets responsibly through an appropriate medicine disposal program rather than household trash or drains.

FAQS

Q1. Why are Dapagliflozin and Metformin combined in one tablet?
Combining both ingredients allows two different mechanisms, kidney-based glucose excretion and liver-based glucose reduction, to work together for more comprehensive blood sugar control.

Q2. Should this tablet be taken with food?
Yes, taking it with meals is generally recommended to reduce stomach-related side effects associated with the Metformin component.

Q3. Does this medicine increase the risk of urinary infections?
Yes, because of the Dapagliflozin component, some patients may experience a higher likelihood of genital or urinary tract infections due to increased glucose in the urine.

Q4. Is extra hydration necessary while taking this medicine?
Yes, maintaining adequate fluid intake is generally advised, since the Dapagliflozin component increases urine output and fluid loss.

Q5. Can this tablet be used in patients with reduced kidney function?
Kidney function is an important factor for both components of this medicine, so a doctor will assess renal health carefully before and during treatment.

Disclaimer

Always use this medicine strictly according to your doctor’s instructions and prescribed dosage.